Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.

被引：0
|
作者：
Gide, Tuba Nur
Quek, Camelia
Madore, Jason
Menzies, Alexander M.
Dent, Rebecca
Carlino, Matteo S.
Guminski, Alex
Saw, Robyn
Thompson, John F.
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
机构：
[1] Univ Sydney, Melanoma Inst Australia, Cent Clin Sch, Fac Med, Sydney, NSW, Australia
[2] Melanoma Inst Australia, Sydney, NSW, Australia
[3] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, North Sydney, Australia
[4] Westmead Hosp, Melanoma Inst Australia, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[5] Blacktown Hosp, Sydney, NSW, Australia
[6] Univ Sydney, Royal North Shore Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[7] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[8] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Sydney, NSW, Australia
[9] Univ Sydney, Melanoma Inst Australia, Sydney Med Sch, Discipline Pathol, Sydney, NSW, Australia
[10] Univ Sydney, Melanoma Inst Australia, Mater Hosp, Royal North Shore Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 07期
关键词：
D O I：
10.1200/JCO.2017.35.7_suppl.51
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
51
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
    Imafuku, Keisuke
    Yoshino, Koji
    Yamaguchi, Kei
    Tsuboi, Satoshi
    Ohara, Kuniaki
    Hata, Hiroo
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e14 - e14
  • [32] Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
    Keisuke Imafuku
    Koji Yoshino
    Kei Yamaguchi
    Satoshi Tsuboi
    Kuniaki Ohara
    Hiroo Hata
    British Journal of Cancer, 2017, 116 : e14 - e14
  • [33] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
    Prithviraj, Prashanth
    McArthur, Grant A.
    Atkinson, Victoria
    Parente, Phillip
    Andrews, Miles Cameron
    Parakh, Sagun
    Cebon, Jonathan S.
    Klein, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Recurrent malignant melanoma of the uterine cervix treated with anti-PD-1 antibodies and anti-CTLA-4 antibodies: A case report
    Sone, Kenbun
    Kukita, Asako
    Masui, Yuri
    Yamada, Daisuke
    Shinozaki-Ushiku, Aya
    Kawata, Akira
    Taguchi, Ayumi
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Iriyama, Takayuki
    Tsuruga, Tetsushi
    Osuga, Yutaka
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (03)
  • [35] Prognostic factors for survival in patients with metastatic skin melanoma, receiving first- line treatment with anti-PD-1 or anti-PD-1 and anti-CTLA-4 immunotherapy regimen at the Instituto Nacional de Cancerolog?a (Bogot?, Colombia)
    Marcela Zuluaga-Liberato, Andrea
    Eduardo Bonilla-Gonzalez, Carlos
    Contreras-Mejia, Fernando
    Alexander Carreno-Duenas, Jose
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2023, 27 (01): : 91 - 102
  • [36] Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials
    Yun, Seongseok
    Vincelette, Nicole D.
    Green, Myke R.
    Hendrickson, Andrea E. Wahner
    Abraham, Ivo
    CANCER MEDICINE, 2016, 5 (07): : 1481 - 1491
  • [37] Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
    Bowyer, Samantha
    Prithviraj, Prashanth
    Lorigan, Paul
    Larkin, James
    McArthur, Grant
    Atkinson, Victoria
    Millward, Michael
    Khou, Muoi
    Diem, Stefan
    Ramanujam, Sangeetha
    Kong, Ben
    Liniker, Elizabeth
    Guminski, Alexander
    Parente, Phillip
    Andrews, Miles C.
    Parakh, Sagun
    Cebon, Jonathan
    Long, Georgina V.
    Carlino, Matteo S.
    Klein, Oliver
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e15 - e15
  • [38] Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
    Samantha Bowyer
    Prashanth Prithviraj
    Paul Lorigan
    James Larkin
    Grant McArthur
    Victoria Atkinson
    Michael Millward
    Muoi Khou
    Stefan Diem
    Sangeetha Ramanujam
    Ben Kong
    Elizabeth Liniker
    Alexander Guminski
    Phillip Parente
    Miles C Andrews
    Sagun Parakh
    Jonathan Cebon
    Georgina V Long
    Matteo S Carlino
    Oliver Klein
    British Journal of Cancer, 2017, 116 : e15 - e15
  • [39] Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
    Klee, Gina
    Kurzhals, Jonas
    Hagelstein, Victoria
    Zillikens, Detlef
    Recke, Andreas
    Langan, Ewan A.
    Terheyden, Patrick
    MELANOMA RESEARCH, 2021, 31 (05) : 464 - 471
  • [40] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
    Kudo, Masatoshi
    LIVER CANCER, 2019, 8 (06) : 413 - 426
12345